Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer

NCT01337154 is registered in ClinicalTrials.gov with CytRx as lead sponsor.

NCT NCT01337154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01337154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects With Advanced Non-Small Cell Lung Cancer
Lead sponsor
CytRx
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2011
Completion date
June 30, 2013
Enrollment
140 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

stage iiib non-small cell lung cancer with pleural effusion, stage iv non-small cell lung cancer